News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
2.170 ^USD	-7.26%		-18.42%	-21.09%

10-08	Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors	CI
10-08	Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell	MT

All News

Mentions Relevance

10-08	Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors	CI
10-08	Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium	AQ
10-08	Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell	MT
10-08	Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors	AQ
10-07	Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium	AQ
10-02	Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026	AQ
09-20	Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index	CI
09-18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
09-14	Perspective Therapeutics, Inc. and Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors	CI
09-14	Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell	MT
09-14	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors	AQ
09-11	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026	AQ
08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
08-11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
08-10	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results	AQ
08-10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-31	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
07-28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
07-28	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
07-17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
07-17	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
07-08	Perspective Therapeutics, Inc. Announces Executive Changes	CI
07-08	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role	MT
07-08	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ